India's Sun Pharmaceutical Industries Ltd. said the U.S. Food and Drug Administration approved its drug Yonsa to treat prostate cancer.
The approval covers use of Yonsa, or abiraterone acetate, in combination with methylprednisolone, to treat patients with metastatic castration-resistant prostate cancer. Pfizer Inc. markets methylprednisolone as Medrol.
Sun Pharmaceutical acquired Yonsa from Churchill Pharmaceuticals LLC, which is entitled to certain up-front and milestone payments, as well as royalties.
Johnson & Johnson unit Janssen Research & Development LLC sells abiraterone acetate under the name Zytiga.
